WilliamTeo personal page - To The Moon

WilliamTeo

WilliamTeo

No personal profile

120Follow

6Followers

0Topic

0Badge

2021-03-22

$GameStop(GME)$diamond hand here

2021-07-17

$Gaotu Techedu Inc.(GOTU)$omg. Trash stock

2021-03-10

Go higher higher

The Equity-Gold Price Conundrum, Part 1: The Great Batsby

2021-05-09

Go for it

Sorry, the original content has been removed

2021-04-26

$Tiger Brokers(TIGR)$cry tiger

2021-08-12

All the way

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster

2021-05-25

Go up and down

Moderna shares once gained more than 4%

2021-04-21

$Snowflake(SNOW)$winter snow

2021-04-02

$CN Energy Group Inc.(CNEY)$when going up

2021-07-03

Go there

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575416215572570","uuid":"3575416215572570","gmtCreate":1612342668405,"gmtModify":1613096802979,"name":"WilliamTeo","pinyin":"williamteo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":120,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.03","exceedPercentage":"93.58%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"80.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":894761578,"gmtCreate":1628858017494,"gmtModify":1676529876690,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894761578","repostId":"2159294386","repostType":4,"isVote":1,"tweetType":1,"viewCount":2496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894990649,"gmtCreate":1628780633881,"gmtModify":1676529854066,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"All the way","listText":"All the way","text":"All the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894990649","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://ttm.financial/m/news/2158325931?lang=en_US&edition=fundamental","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2910,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896402641,"gmtCreate":1628599016083,"gmtModify":1676529791712,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Lose money","listText":"Lose money","text":"Lose money","images":[{"img":"https://static.tigerbbs.com/942135289525db288b1954e466ab1309","width":"1080","height":"3610"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896402641","isVote":1,"tweetType":1,"viewCount":2181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":896406724,"gmtCreate":1628598970368,"gmtModify":1676529791680,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"To the sun","listText":"To the sun","text":"To the sun","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896406724","repostId":"1116005404","repostType":4,"repost":{"id":"1116005404","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628582673,"share":"https://ttm.financial/m/news/1116005404?lang=en_US&edition=fundamental","pubTime":"2021-08-10 16:04","market":"us","language":"en","title":"AMC shares rose 7% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1116005404","media":"Tiger Newspress","summary":"AMC shares rose 7% in premarket trading.\nAMC Entertainment reported a narrower than expected loss fo","content":"<p>AMC&nbsp;shares rose 7% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/692b6fc550595ea189d7b6697732bdac\" tg-width=\"854\" tg-height=\"608\" referrerpolicy=\"no-referrer\">AMC Entertainment&nbsp;reported&nbsp;a narrower than expected loss for the second quarter while revenue topped estimates.</p>\n<p>AMC&nbsp;will begin accepting apex cryptocurrency&nbsp;<b>Bitcoin</b>&nbsp;as payment for move tickets and concessions by the end of this&nbsp;year.</p>\n<p>“By year end, we will have the information technology system in place to accept Bitcoin as payment for movie tickets and concessions if purchased online at all of our U.S. theatres,” AMC Entertainment CEO&nbsp;<b>Adam Aron</b>&nbsp;said on&nbsp;the Q2 earnings call on Monday.</p>\n<p>Aron added that AMC Entertainment is in the preliminary stages of exploring how else the company can participate in the new “burgeoning cryptocurrency universe.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC shares rose 7% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC shares rose 7% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-10 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC&nbsp;shares rose 7% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/692b6fc550595ea189d7b6697732bdac\" tg-width=\"854\" tg-height=\"608\" referrerpolicy=\"no-referrer\">AMC Entertainment&nbsp;reported&nbsp;a narrower than expected loss for the second quarter while revenue topped estimates.</p>\n<p>AMC&nbsp;will begin accepting apex cryptocurrency&nbsp;<b>Bitcoin</b>&nbsp;as payment for move tickets and concessions by the end of this&nbsp;year.</p>\n<p>“By year end, we will have the information technology system in place to accept Bitcoin as payment for movie tickets and concessions if purchased online at all of our U.S. theatres,” AMC Entertainment CEO&nbsp;<b>Adam Aron</b>&nbsp;said on&nbsp;the Q2 earnings call on Monday.</p>\n<p>Aron added that AMC Entertainment is in the preliminary stages of exploring how else the company can participate in the new “burgeoning cryptocurrency universe.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116005404","content_text":"AMC shares rose 7% in premarket trading.\nAMC Entertainment reported a narrower than expected loss for the second quarter while revenue topped estimates.\nAMC will begin accepting apex cryptocurrency Bitcoin as payment for move tickets and concessions by the end of this year.\n“By year end, we will have the information technology system in place to accept Bitcoin as payment for movie tickets and concessions if purchased online at all of our U.S. theatres,” AMC Entertainment CEO Adam Aron said on the Q2 earnings call on Monday.\nAron added that AMC Entertainment is in the preliminary stages of exploring how else the company can participate in the new “burgeoning cryptocurrency universe.”","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2352,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896406617,"gmtCreate":1628598943439,"gmtModify":1676529791688,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Pro","listText":"Pro","text":"Pro","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896406617","repostId":"1122891084","repostType":4,"repost":{"id":"1122891084","kind":"news","pubTimestamp":1628585720,"share":"https://ttm.financial/m/news/1122891084?lang=en_US&edition=fundamental","pubTime":"2021-08-10 16:55","market":"us","language":"en","title":"Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time","url":"https://stock-news.laohu8.com/highlight/detail?id=1122891084","media":"Seeking Alpha","summary":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE ","content":"<ul>\n <li>According to two reports published in medRxiv, the mRNA vaccine developed by <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>&nbsp;may be less effective than <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a>'s&nbsp;against the Delta variant of the coronavirus,&nbsp;<i>Reuters reports</i>.</li>\n <li>The study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.</li>\n <li>Researchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.</li>\n <li>However, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.</li>\n <li>While both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.</li>\n <li>In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.</li>\n <li>\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.</li>\n <li>In a study&nbsp;posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.</li>\n <li>The data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.</li>\n <li>Overall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.</li>\n <li>At all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.</li>\n <li>Among patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.</li>\n <li>\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.</li>\n <li>Israel has already started administering booster shots to people over the age of 60.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna COVID-19 vaccine may be better than Pfizer against Delta variant; breakthrough cases rise with time\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 16:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters ...</p>\n\n<a href=\"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3727988-moderna-covid-19-vaccine-may-be-better-than-pfizer-against-delta-variant-breakthrough-cases-rise-with-time","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122891084","content_text":"According to two reports published in medRxiv, the mRNA vaccine developed by Pfizer and BioNTech SE may be less effective than Moderna, Inc.'s against the Delta variant of the coronavirus, Reuters reports.\nThe study, yet to be peer reviewed, included more than 50,000 patients in the Mayo Clinic Health System.\nResearchers found that efficacy of Moderna's Covid-19 vaccine dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.\nHowever, during the same time, Pfizer/BioNTech vaccine's effectiveness decreased to 42% from 76%.\nWhile both vaccines remain effective at preventing Covid hospitalization, a Moderna booster shot may be necessary soon for people who got Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company, who led the Mayo study.\nIn a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially against variants - after the Moderna shot than after Pfizer/BioNTech vaccine.\n\"We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection,\" said a Pfizer spokesperson.\nIn a study posted on medRxiv, it was observed that breakthrough COVID-19 odds rise months after vaccination.\nThe data suggested that people who received their second dose of the Pfizer/BioNTech vaccine five or more months ago are more likely to test positive for COVID-19 than people who were fully vaccinated less than five months ago.\nOverall, 1.8% of individulas tested positive in a research including nearly 34,000 fully vaccinated adults in Israel which were tested to see if they had a breakthrough case of COVID-19.\nAt all ages, the odds of testing positive were higher when the last vaccine dose was received at least 146 days earlier.\nAmong patients older than 60, the odds of a positive test were almost three times higher when 146 days had passed since the second dose.\n\"Very few patients had required hospitalization, and it is too early to assess the severity of these new infections in terms of hospital admission, need for mechanical ventilation or mortality,\" he added. \"We are planning to continue our research,\" said coauthor Dr. Eugene Merzon of Leumit Health Services in Israel.\nIsrael has already started administering booster shots to people over the age of 60.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893119227,"gmtCreate":1628245138469,"gmtModify":1703503866100,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"All the way","listText":"All the way","text":"All the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893119227","repostId":"1135651416","repostType":4,"isVote":1,"tweetType":1,"viewCount":2073,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806534198,"gmtCreate":1627666751414,"gmtModify":1703494456187,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"To the sun","listText":"To the sun","text":"To the sun","images":[{"img":"https://static.tigerbbs.com/edc1f1e47b16e96a42d7ec21bf988e3c","width":"1080","height":"3691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806534198","isVote":1,"tweetType":1,"viewCount":2412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808042660,"gmtCreate":1627547020950,"gmtModify":1703492090475,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EBON\">$Ebang International Holdings Inc.(EBON)$</a>not meant to be","listText":"<a href=\"https://laohu8.com/S/EBON\">$Ebang International Holdings Inc.(EBON)$</a>not meant to be","text":"$Ebang International Holdings Inc.(EBON)$not meant to be","images":[{"img":"https://static.tigerbbs.com/481041af7db4ea49f66170c2f8001a68","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808042660","isVote":1,"tweetType":1,"viewCount":2609,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175423584,"gmtCreate":1627047386448,"gmtModify":1703483213119,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Trash stock","listText":"Trash stock","text":"Trash stock","images":[{"img":"https://static.tigerbbs.com/c2a7977bbebb8a789f10da9a7ff17a88","width":"1080","height":"3691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175423584","isVote":1,"tweetType":1,"viewCount":2075,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175429165,"gmtCreate":1627047351657,"gmtModify":1703483211654,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"To the moon","listText":"To the moon","text":"To the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/175429165","repostId":"2153498346","repostType":4,"isVote":1,"tweetType":1,"viewCount":3362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176634432,"gmtCreate":1626879223426,"gmtModify":1703479881545,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Unreasonable","listText":"Unreasonable","text":"Unreasonable","images":[{"img":"https://static.tigerbbs.com/c47f8c09fbac996a5bad78b0075ac046","width":"1080","height":"3691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176634432","isVote":1,"tweetType":1,"viewCount":1164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179393598,"gmtCreate":1626485012014,"gmtModify":1703760920805,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>omg. Trash stock","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>omg. Trash stock","text":"$Gaotu Techedu Inc.(GOTU)$omg. Trash stock","images":[{"img":"https://static.tigerbbs.com/6c28595f6d5a7673fb76b17b1c6320fd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/179393598","isVote":1,"tweetType":1,"viewCount":1566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147822526,"gmtCreate":1626351695365,"gmtModify":1703758426380,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Up the lorry&nbsp;","listText":"Up the lorry&nbsp;","text":"Up the lorry","images":[{"img":"https://static.tigerbbs.com/7d195ba504666aa9c1d493e565d9fa90","width":"1080","height":"3571"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147822526","isVote":1,"tweetType":1,"viewCount":584,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":147822270,"gmtCreate":1626351668090,"gmtModify":1703758426218,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"All the way","listText":"All the way","text":"All the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147822270","repostId":"2151251345","repostType":4,"repost":{"id":"2151251345","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626343025,"share":"https://ttm.financial/m/news/2151251345?lang=en_US&edition=fundamental","pubTime":"2021-07-15 17:57","market":"us","language":"en","title":"UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2151251345","media":"Benzinga","summary":"UnitedHealth Group (NYSE:UNH) reported quarterly earnings of $4.70 per share which beat the analyst consensus estimate of $4.43 by 6.09 percent. This is a 33.99 percent decrease over earnings of $7.12 per share from the","content":"<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-15 17:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNH":"联合健康","QTWO":"Q2 Holdings Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151251345","content_text":"UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.\nThe industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.\nFor the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.\nNearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.\nRevenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.\nUnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.\nThe company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.","news_type":1,"symbols_score_info":{"UNH":0.9,"QTWO":0.9}},"isVote":1,"tweetType":1,"viewCount":753,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147822126,"gmtCreate":1626351647465,"gmtModify":1703758425732,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"All the way down","listText":"All the way down","text":"All the way down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147822126","repostId":"2151251345","repostType":4,"repost":{"id":"2151251345","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626343025,"share":"https://ttm.financial/m/news/2151251345?lang=en_US&edition=fundamental","pubTime":"2021-07-15 17:57","market":"us","language":"en","title":"UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2151251345","media":"Benzinga","summary":"UnitedHealth Group (NYSE:UNH) reported quarterly earnings of $4.70 per share which beat the analyst consensus estimate of $4.43 by 6.09 percent. This is a 33.99 percent decrease over earnings of $7.12 per share from the","content":"<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnitedHealth Group Q2 EPS $4.70 Beats $4.43 Estimate, Sales $71.30B Beat $69.45B Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-15 17:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.</p>\n<p>The industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.</p>\n<p>For the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.</p>\n<p>Nearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.</p>\n<p>Revenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.</p>\n<p>UnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.</p>\n<p>The company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNH":"联合健康","QTWO":"Q2 Holdings Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151251345","content_text":"UnitedHealth Group Inc beat quarterly profit estimates and raised its full-year earnings target on Thursday, as the largest U.S. health insurer reported strong growth in its Optum unit that manages drug benefits.\nThe industry bellwether raised its full-year profit target for the second time this year, and now expects adjusted earnings of $18.30 to $18.80 per share in 2021, compared with its previous forecast of $18.10 to $18.60.\nFor the quarter ended June 30, the company reported a medical loss ratio - the percentage of collected premiums spent on medical services - of 82.8%, compared with 70.2% a year earlier, when patients put off non-urgent care due to the COVID-19 pandemic.\nNearly half of all Americans have been fully vaccinated according to latest government data and daily new COVID-19 cases ebbed in May and June, encouraging people to return to doctors' offices for routine, non-elective medical care.\nRevenue from UnitedHealth's Optum unit, which manages drug benefits and offers healthcare data analytics services, rose 17.2% to $38.3 billion from a year earlier.\nUnitedHealth reported adjusted earnings of $4.70 per share, beating estimates of $4.43 per share, according to IBES data from Refinitiv.\nThe company has beaten Wall Street's expectations for earnings per share for at least the last eight quarters.","news_type":1,"symbols_score_info":{"UNH":0.9,"QTWO":0.9}},"isVote":1,"tweetType":1,"viewCount":860,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146539505,"gmtCreate":1626089102907,"gmtModify":1703753089512,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Slowly but surely. Target $18","listText":"Slowly but surely. Target $18","text":"Slowly but surely. Target $18","images":[{"img":"https://static.tigerbbs.com/6bc509e907310e577e7b32e0d7f1bb08","width":"1080","height":"3472"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146539505","isVote":1,"tweetType":1,"viewCount":663,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":146530565,"gmtCreate":1626089052357,"gmtModify":1703753087871,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Wow this&nbsp;","listText":"Wow this&nbsp;","text":"Wow this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146530565","repostId":"2150538413","repostType":4,"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146530690,"gmtCreate":1626089026910,"gmtModify":1703753087704,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/146530690","repostId":"1114863871","repostType":4,"repost":{"id":"1114863871","kind":"news","pubTimestamp":1626039626,"share":"https://ttm.financial/m/news/1114863871?lang=en_US&edition=fundamental","pubTime":"2021-07-12 05:40","market":"us","language":"en","title":"Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1114863871","media":"Barron's","summary":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% a","content":"<p>Second-quarter earnings season gets under way&nbsp;this week, with several big banks reporting.&nbsp;JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.</p>\n<p>Other major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.</p>\n<p>The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday,&nbsp;followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.</p>\n<p>Investors and economists will also get a look at a pair of sentiment surveys this week:&nbsp;The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The&nbsp;Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.</p>\n<p><img src=\"https://static.tigerbbs.com/1508a89eaa3fb959feaaa832797a2c48\" tg-width=\"1176\" tg-height=\"360\"></p>\n<p><b>Monday 7/12</b></p>\n<p>FedExhosts a conference call to update the investment community on its business outlook.</p>\n<p><b>Tuesday 7/13</b></p>\n<p>JPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.</p>\n<p>Conagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.</p>\n<p>Dell Technologieshosts a conference call to discuss its ESG strategy.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.</p>\n<p><b>The National Federation</b>&nbsp;of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.</p>\n<p><b>Wednesday 7/14</b></p>\n<p>Bank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.</p>\n<p><b>The Federal Reserve</b>&nbsp;releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.</p>\n<p><b>The BLS releases</b>&nbsp;the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.</p>\n<p><b>Thursday 7/15</b></p>\n<p>Bank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.</p>\n<p><b>Friday 7/16</b></p>\n<p>Charles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.</p>\n<p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.</p>\n<p><b>The University of Michigan</b>&nbsp;releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.</p>\n<p><b>The Census Bureau</b>&nbsp;reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 05:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","TSM":"台积电","JPM":"摩根大通","BAC":"美国银行","C":"花旗","WFC":"富国银行","MS":"摩根士丹利"},"source_url":"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114863871","content_text":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.\nOther major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.\nThe week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.\nInvestors and economists will also get a look at a pair of sentiment surveys this week: The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.\n\nMonday 7/12\nFedExhosts a conference call to update the investment community on its business outlook.\nTuesday 7/13\nJPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.\nConagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.\nDell Technologieshosts a conference call to discuss its ESG strategy.\nThe Bureau of Labor Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.\nThe National Federation of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.\nWednesday 7/14\nBank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.\nThe Federal Reserve releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.\nThe BLS releases the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.\nThursday 7/15\nBank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.\nFriday 7/16\nCharles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.\nThe Bank of Japan announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.\nThe University of Michigan releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.\nThe Census Bureau reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.","news_type":1,"symbols_score_info":{"GS":0.9,"JPM":0.9,"WFC":0.9,"TSM":0.9,"C":0.9,"BAC":0.9,"MS":0.9}},"isVote":1,"tweetType":1,"viewCount":1007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141549674,"gmtCreate":1625882430398,"gmtModify":1703750352197,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"All the way","listText":"All the way","text":"All the way","images":[{"img":"https://static.tigerbbs.com/72bbe6a315f54d7217be8dba61768a24","width":"1080","height":"3571"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141549674","isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":141540425,"gmtCreate":1625882401567,"gmtModify":1703750350567,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3575416215572570","authorIdStr":"3575416215572570"},"themes":[],"htmlText":"Lets go","listText":"Lets go","text":"Lets go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141540425","repostId":"2150305430","repostType":4,"repost":{"id":"2150305430","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625874020,"share":"https://ttm.financial/m/news/2150305430?lang=en_US&edition=fundamental","pubTime":"2021-07-10 07:40","market":"us","language":"en","title":"FTC extends probe of Amazon, MGM deal - source","url":"https://stock-news.laohu8.com/highlight/detail?id=2150305430","media":"Reuters","summary":"WASHINGTON, July 9 (Reuters) - Amazon.com's deal to buy movie studio MGM for $8.5 billion is headed ","content":"<p>WASHINGTON, July 9 (Reuters) - Amazon.com's deal to buy movie studio MGM for $8.5 billion is headed for an extended probe by the Federal Trade Commission, after a source familiar with the matter said on Friday the agency had issued a second request in its review of the merger.</p>\n<p>Issuing a second request indicated that it would likely take months for the agency to rule on the deal.</p>\n<p>The Information was first to report the lengthier probe.</p>\n<p>Amazon said in May that it would buy the U.S. movie studio, home to the James Bond franchise, which would give it a huge library of films and TV shows to compete with streaming rivals like Netflix and Disney+.</p>\n<p>In June, Amazon asked that FTC Chair Lina Khan be recused on antitrust matters related to the online retail giant because of research that she had done and her previous advocacy.</p>\n<p>In addition to reviewing the merger, the agency is investigating Amazon as part of a series of probes underway into Big Tech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FTC extends probe of Amazon, MGM deal - source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFTC extends probe of Amazon, MGM deal - source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-10 07:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>WASHINGTON, July 9 (Reuters) - Amazon.com's deal to buy movie studio MGM for $8.5 billion is headed for an extended probe by the Federal Trade Commission, after a source familiar with the matter said on Friday the agency had issued a second request in its review of the merger.</p>\n<p>Issuing a second request indicated that it would likely take months for the agency to rule on the deal.</p>\n<p>The Information was first to report the lengthier probe.</p>\n<p>Amazon said in May that it would buy the U.S. movie studio, home to the James Bond franchise, which would give it a huge library of films and TV shows to compete with streaming rivals like Netflix and Disney+.</p>\n<p>In June, Amazon asked that FTC Chair Lina Khan be recused on antitrust matters related to the online retail giant because of research that she had done and her previous advocacy.</p>\n<p>In addition to reviewing the merger, the agency is investigating Amazon as part of a series of probes underway into Big Tech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGM":"美高梅","AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150305430","content_text":"WASHINGTON, July 9 (Reuters) - Amazon.com's deal to buy movie studio MGM for $8.5 billion is headed for an extended probe by the Federal Trade Commission, after a source familiar with the matter said on Friday the agency had issued a second request in its review of the merger.\nIssuing a second request indicated that it would likely take months for the agency to rule on the deal.\nThe Information was first to report the lengthier probe.\nAmazon said in May that it would buy the U.S. movie studio, home to the James Bond franchise, which would give it a huge library of films and TV shows to compete with streaming rivals like Netflix and Disney+.\nIn June, Amazon asked that FTC Chair Lina Khan be recused on antitrust matters related to the online retail giant because of research that she had done and her previous advocacy.\nIn addition to reviewing the merger, the agency is investigating Amazon as part of a series of probes underway into Big Tech.","news_type":1,"symbols_score_info":{"MGM":0.9,"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":359501806,"gmtCreate":1616408868405,"gmtModify":1704793644992,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>diamond hand here","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>diamond hand here","text":"$GameStop(GME)$diamond hand here","images":[{"img":"https://static.tigerbbs.com/f1d3f5f8e935639ce808309299a869c8","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/359501806","isVote":1,"tweetType":1,"viewCount":1798,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3499891542239139","authorId":"3499891542239139","name":"小小虎儿儿","avatar":"https://static.tigerbbs.com/80d9d31f798bff492018b73985e9b525","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3499891542239139","idStr":"3499891542239139"},"content":"What does it mean?","text":"What does it mean?","html":"What does it mean?"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":179393598,"gmtCreate":1626485012014,"gmtModify":1703760920805,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>omg. Trash stock","listText":"<a href=\"https://laohu8.com/S/GOTU\">$Gaotu Techedu Inc.(GOTU)$</a>omg. Trash stock","text":"$Gaotu Techedu Inc.(GOTU)$omg. Trash stock","images":[{"img":"https://static.tigerbbs.com/6c28595f6d5a7673fb76b17b1c6320fd","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/179393598","isVote":1,"tweetType":1,"viewCount":1566,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":323792151,"gmtCreate":1615373252973,"gmtModify":1704781822201,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"Go higher higher","listText":"Go higher higher","text":"Go higher higher","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/323792151","repostId":"1162030727","repostType":4,"repost":{"id":"1162030727","kind":"news","pubTimestamp":1615371076,"share":"https://ttm.financial/m/news/1162030727?lang=en_US&edition=fundamental","pubTime":"2021-03-10 18:11","market":"us","language":"en","title":"The Equity-Gold Price Conundrum, Part 1: The Great Batsby","url":"https://stock-news.laohu8.com/highlight/detail?id=1162030727","media":"zerohedge","summary":"The relentless rally in equity markets has pushed valuations to extreme levels based on traditional ","content":"<p>The relentless rally in equity markets has pushed valuations to extreme levels based on traditional metrics. In this report, we analyze the two common arguments made by equity bulls on why this time is different and current valuations are justified. We find that either gold or equities are currently mispriced, as, a) both arguments would imply that gold should outperform stocks and b) if neither of the scenarios play out, equities are due for a substantial correction.</p><p><img src=\"https://static.tigerbbs.com/95f7609bf84bf26bd5d2443fa9a7de86\" tg-width=\"500\" tg-height=\"445\" referrerpolicy=\"no-referrer\">Amidst the global COVID-19 pandemic, equities had staggering rally over the past 12 months. The S&amp;P500 almost doubled in less than a year from a low of 2240 on March 23, 2020 to currently 3860 at the time of writing. In addition, some narrower indices have done even better. Particularly certain technology stocks have relentlessly risen amidst an environment of economic stress.</p><p>This has led to a sharp increase in the equities-to-gold price ratio (see Exhibit 1) even as economic growth has collapsed while the Fed increased its balance sheet at an unprecedented level.</p><p><img src=\"https://static.tigerbbs.com/a828b10b92375dfb19347e6c59314c83\" tg-width=\"500\" tg-height=\"405\" referrerpolicy=\"no-referrer\"></p><p>This increase in the equities-to-gold-ratio is not caused by gold performing poorly as prices for the yellow metal are up12% since the end of 2019. It’s simply a consequence of equities’ doing really well. But equity valuations according to traditional metrics have now approached extreme levels. For example, the total market cap to GDP (Buffet indicator) is currently at 193% (see exhibit 2), the highest on record, 50% above the peak during the dot.com bubble.</p><p><img src=\"https://static.tigerbbs.com/e64899d2c53b18cc97b2dce33717c9af\" tg-width=\"500\" tg-height=\"428\" referrerpolicy=\"no-referrer\">Moreover, global equities to GDP are also extremely high, currently at &gt;120% (see exhibit 3).</p><p><img src=\"https://static.tigerbbs.com/ef426becc1777204ae2f18e3c290e2e6\" tg-width=\"500\" tg-height=\"436\" referrerpolicy=\"no-referrer\">The Cyclically Adjusted Price Earnings Ratio, or CAPE, a measure developed by Robert Schiller, is also flashing red with the second highest reading in history going back to the late 1900s (see exhibit 4).</p><p><img src=\"https://static.tigerbbs.com/8cc92db52653acc17b59de9311c17bf0\" tg-width=\"500\" tg-height=\"442\" referrerpolicy=\"no-referrer\">Price to sales ratios also hit a record high (see Exhibit 5).</p><p><img src=\"https://static.tigerbbs.com/a119fa360112d18ced5d8efff557ebea\" tg-width=\"500\" tg-height=\"436\" referrerpolicy=\"no-referrer\">There are other indicators that suggest that equity prices have detached from underlying fundamentals. The put / call ratio on the CBOE has now reached the levels of the dot.com bubble (see Exhibit 6).</p><p><img src=\"https://static.tigerbbs.com/462aa5d4dee82e50792b2a4f6bbd70f8\" tg-width=\"500\" tg-height=\"389\" referrerpolicy=\"no-referrer\">We also saw an unprecedented inflow of new market participants. People with very little or no market exp4erience opened online brokerage accounts at an unprecedented speed during the global lockdowns. More than 10 million Americans opened a trading account in 2020 according to the Wall Street Journal.&nbsp; According to CNBC, ten percent of Americans bought a stock for the first time in the past 12 months, and a staggering twenty-two percent of Gen Z (currently 6-24 years old) opened a stock market account in the last 12 months.</p><p>And stocks are not the only assets that are skyrocketing. Cryptocurrencies, which since 2017 had temporarily lost their luster, are rallying at breakneck pace since the outbreak of the pandemic (see exhibit 7).</p><p><img src=\"https://static.tigerbbs.com/46a4f01c4a7404c0a7b196d39dac0a78\" tg-width=\"500\" tg-height=\"424\" referrerpolicy=\"no-referrer\">Judged on only those metrics, stock markets are clearly in a bubble. But is this time maybe really different as the bulls argue? In our view, there are only two ways that current stock prices could indeed be justified;</p><blockquote><b>1. The great Gatsby:</b>The pandemic, as negative as it was for economic activity near term, will be followed by a period of unprecedented economic expansion. Hence, GDP will rapidly rise and close the gap to equity prices. <b>2. The great inflation:</b>Stocks simply price in future inflation that eventually will come on the back of decades of ultra-low rates and central bank balance sheet expansion</blockquote><p>We will take a close look at the validity of those scenarios below. As we will show, these scenarios would require that we enter a multi-year period of extreme economic growth or inflation or a mix of both.&nbsp; However, we will show that gold should outperform stocks in either scenario. And if neither scenario comes true, then stock markets are due for a substantial correction. In that scenario, we would expect central banks to eventually intervene, which should ultimately also benefit gold. Hence, the fact that stocks have vastly outperformed gold over the past months is somewhat of a conundrum. But we are confident that this will reverse going forward.</p><p><b>Scenario one: The great Gatsby</b></p><p>Proponents of the great Gatsby scenario argue that, once the COVID19 pandemic is behind us as enough people are vaccinated and normality returns, economic activity will explode. The argumentation goes that there is a lot of pent-up demand as people were forced to save during the lockdowns and are eager to consume. This demand will be further fueled by stimulus checks (potentially in perpetuity, UBI). At the same time, governments around the world are rolling out huge green infrastructure programs, partially to combat climate change and partially to jump-start the economy.</p><p>While some of these deliberations have merit, there are a few important caveats. In our view, it is extremely unlikely for the economy to simply pick up where we left even if the current measures intended to contain the pandemic are completely removed. Many small businesses have closed forever or are about to close in the near term. The surviving businesses are aggressively cutting costs by a) laying off staff and b) trimming production. The former will impact on consumer demand going forward, the latter will impact on the businesses that are further up in the production chain. While there may be pent-up consumer demand from those who still have a job and saved a lot of money during lockdowns, there are also likely to be a lot of pent-up bankruptcies as many businesses have simply survived so far due to government intervention. Eventually many of those businesses will close. This is especially true in many European economies where governments de facto paid companies not to fire people.</p><p>The problem is compounded by the fact that the economy was already stuttering long before Coronavirus became a household name. The Fed had to aggressively reverse its hiking cycle already by 3Q2019 as markets started to turn sour. We believe that we are close to or already in a recession by late 2019. Hence, a simple return to the pre-COVID economy would mean back to a “normal” recession. Thus, the drivers for this apparent future multi-year super growth cycle have to be strong enough to offset these bearish factors as well.</p><p>Then there is the magnitude by how much the economy would have to expand to justify these kind of equity valuations. If you take a simple metric like market cap to GDP, then GDP would have to almost double from current levels to be in line with historical averages. That implies a nominal GDP of $40tn, or 86% above the levels before COVID (average 2019). Granted that market cap to GDP was already inflated to around 1.2 on average in the ten years prior to the pandemic due to ultra-low interest rates, a return to that average would still require nominal GDP to rise to $35tn or 63% from pre-COVID levels.</p><p>Even with a staggering 5% annual GDP growth and 2% inflation, it would still take more than seven years to get there. Are stocks really pricing in the year 2028 with 0% discount rate? And if so, what would be the fundamental driver to push stocks even higher from here? &nbsp;And is there even historic precedent for these kind of growth numbers? In the post WWII period, there have been only two instances where economic expansion was that high for a prolonged period (see Exhibit 8).</p><p>After WWII ended, the US saw a few years of moderate growth as government spending plummeted, followed by very high growth rates at around 6.9% between 1949 and 1953. This was possible as the US was one of the very few countries where none of the infrastructure had been destroyed and the rest of the world had to be rebuilt. However mathematically, even a repetition of the 1949-53 growth period over the coming years would not be enough to justify current stock prices as it lasted for “only” four years before the US fell into another recession.</p><p><img src=\"https://static.tigerbbs.com/e0e3916e88c1ee473c5ea235b229f969\" tg-width=\"500\" tg-height=\"420\" referrerpolicy=\"no-referrer\">From 1958-1969, the US economy was able to grow close to 5% with a brief monetary recession in 1960. In our view, this 1960s growth period is the only one that reflects the magnitude and length needed to get US GDP back in line with current equity prices. However, the economic environment of the 1960s looked very different from where we are now. More specifically, the US exited WWII with record debt to GPD of over 100%. However, it then immediately cut spending (which resulted in the slower growth rates in the immediate years after WWII) and reduced debt. Inflation also picked up, which, to some extent, helped reducing debt even further[1]. By 1959, the US government had reduced its debt held by the public to 44%, and it dropped to 27% by the end of the 60s (see exhibit 9).</p><p><img src=\"https://static.tigerbbs.com/4ee79afe5f74fa39abc86b197930c486\" tg-width=\"500\" tg-height=\"422\" referrerpolicy=\"no-referrer\">Additionally, 10-year treasury rates average at around 5% during this entire growth period. This is a stark contrast to the 1.5% we are seeing now (which already seem to rattle markets). Furthermore, the FED has no room to the downside, as Fed funds rates are already at zero percent. Hence, the only monetary stimulus that is left is via continued and even more extreme QE. However, as we have shown many times before (see&nbsp;Gold Price Framework Vol. 2: The energy side of the equation,&nbsp;<i>28 May 2018</i>), QE has always a huge and direct effect on gold prices, and gold is currently not pricing any of that in. Instead, the equity and gold markets seem to be pricing in economic expansion that is driven by anything but more monetary stimulus.</p><p>Another theme of the great Gatsby scenario is that governments will unleash massive transformation towards a greener future. This will lead to huge infrastructure investments in energy, transportation and commodity space, create jobs and unlock economic growth. While we believe that this is likely to be true, what the market seems to ignore is that this can only be financed with more government debt. Central banks will ultimately have to buy that debt, which has the same effect as QE as it leads to a growing balance sheet. And as we have outlined before, higher QE leads to higher gold prices. So again, if markets are pricing in economic expansion on the back of a “green new deal”, they seem to wrongly assume that this can be done without an effect on gold price.</p><p>Lastly, there is the idea that the COVID relief checks will continue indefinitely, de facto introducing a sort of Universal Basic Income (UBI). This would have an effect on consumer spending and, thus, corporate revenues. However, currently the US is running the largest deficit in history. If UBI becomes a reality, this would also have to be entirely financed via debt. As mentioned before, markets are not pricing this in, otherwise we would see an effect on gold.</p><p><b>Thus, the equity-gold conundrum doesn’t disappear in the great Gatsby scenario. In fact, we think that if we see strong economic growth over the coming years, it will entirely be debt financed and as a consequence gold should outperform stocks, not the other way around.</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Equity-Gold Price Conundrum, Part 1: The Great Batsby</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Equity-Gold Price Conundrum, Part 1: The Great Batsby\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-10 18:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/equity-gold-price-conundrum-part-1-great-batsby?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohege%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The relentless rally in equity markets has pushed valuations to extreme levels based on traditional metrics. In this report, we analyze the two common arguments made by equity bulls on why this time ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/equity-gold-price-conundrum-part-1-great-batsby?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohege%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.zerohedge.com/markets/equity-gold-price-conundrum-part-1-great-batsby?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohege%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162030727","content_text":"The relentless rally in equity markets has pushed valuations to extreme levels based on traditional metrics. In this report, we analyze the two common arguments made by equity bulls on why this time is different and current valuations are justified. We find that either gold or equities are currently mispriced, as, a) both arguments would imply that gold should outperform stocks and b) if neither of the scenarios play out, equities are due for a substantial correction.Amidst the global COVID-19 pandemic, equities had staggering rally over the past 12 months. The S&P500 almost doubled in less than a year from a low of 2240 on March 23, 2020 to currently 3860 at the time of writing. In addition, some narrower indices have done even better. Particularly certain technology stocks have relentlessly risen amidst an environment of economic stress.This has led to a sharp increase in the equities-to-gold price ratio (see Exhibit 1) even as economic growth has collapsed while the Fed increased its balance sheet at an unprecedented level.This increase in the equities-to-gold-ratio is not caused by gold performing poorly as prices for the yellow metal are up12% since the end of 2019. It’s simply a consequence of equities’ doing really well. But equity valuations according to traditional metrics have now approached extreme levels. For example, the total market cap to GDP (Buffet indicator) is currently at 193% (see exhibit 2), the highest on record, 50% above the peak during the dot.com bubble.Moreover, global equities to GDP are also extremely high, currently at >120% (see exhibit 3).The Cyclically Adjusted Price Earnings Ratio, or CAPE, a measure developed by Robert Schiller, is also flashing red with the second highest reading in history going back to the late 1900s (see exhibit 4).Price to sales ratios also hit a record high (see Exhibit 5).There are other indicators that suggest that equity prices have detached from underlying fundamentals. The put / call ratio on the CBOE has now reached the levels of the dot.com bubble (see Exhibit 6).We also saw an unprecedented inflow of new market participants. People with very little or no market exp4erience opened online brokerage accounts at an unprecedented speed during the global lockdowns. More than 10 million Americans opened a trading account in 2020 according to the Wall Street Journal.  According to CNBC, ten percent of Americans bought a stock for the first time in the past 12 months, and a staggering twenty-two percent of Gen Z (currently 6-24 years old) opened a stock market account in the last 12 months.And stocks are not the only assets that are skyrocketing. Cryptocurrencies, which since 2017 had temporarily lost their luster, are rallying at breakneck pace since the outbreak of the pandemic (see exhibit 7).Judged on only those metrics, stock markets are clearly in a bubble. But is this time maybe really different as the bulls argue? In our view, there are only two ways that current stock prices could indeed be justified;1. The great Gatsby:The pandemic, as negative as it was for economic activity near term, will be followed by a period of unprecedented economic expansion. Hence, GDP will rapidly rise and close the gap to equity prices. 2. The great inflation:Stocks simply price in future inflation that eventually will come on the back of decades of ultra-low rates and central bank balance sheet expansionWe will take a close look at the validity of those scenarios below. As we will show, these scenarios would require that we enter a multi-year period of extreme economic growth or inflation or a mix of both.  However, we will show that gold should outperform stocks in either scenario. And if neither scenario comes true, then stock markets are due for a substantial correction. In that scenario, we would expect central banks to eventually intervene, which should ultimately also benefit gold. Hence, the fact that stocks have vastly outperformed gold over the past months is somewhat of a conundrum. But we are confident that this will reverse going forward.Scenario one: The great GatsbyProponents of the great Gatsby scenario argue that, once the COVID19 pandemic is behind us as enough people are vaccinated and normality returns, economic activity will explode. The argumentation goes that there is a lot of pent-up demand as people were forced to save during the lockdowns and are eager to consume. This demand will be further fueled by stimulus checks (potentially in perpetuity, UBI). At the same time, governments around the world are rolling out huge green infrastructure programs, partially to combat climate change and partially to jump-start the economy.While some of these deliberations have merit, there are a few important caveats. In our view, it is extremely unlikely for the economy to simply pick up where we left even if the current measures intended to contain the pandemic are completely removed. Many small businesses have closed forever or are about to close in the near term. The surviving businesses are aggressively cutting costs by a) laying off staff and b) trimming production. The former will impact on consumer demand going forward, the latter will impact on the businesses that are further up in the production chain. While there may be pent-up consumer demand from those who still have a job and saved a lot of money during lockdowns, there are also likely to be a lot of pent-up bankruptcies as many businesses have simply survived so far due to government intervention. Eventually many of those businesses will close. This is especially true in many European economies where governments de facto paid companies not to fire people.The problem is compounded by the fact that the economy was already stuttering long before Coronavirus became a household name. The Fed had to aggressively reverse its hiking cycle already by 3Q2019 as markets started to turn sour. We believe that we are close to or already in a recession by late 2019. Hence, a simple return to the pre-COVID economy would mean back to a “normal” recession. Thus, the drivers for this apparent future multi-year super growth cycle have to be strong enough to offset these bearish factors as well.Then there is the magnitude by how much the economy would have to expand to justify these kind of equity valuations. If you take a simple metric like market cap to GDP, then GDP would have to almost double from current levels to be in line with historical averages. That implies a nominal GDP of $40tn, or 86% above the levels before COVID (average 2019). Granted that market cap to GDP was already inflated to around 1.2 on average in the ten years prior to the pandemic due to ultra-low interest rates, a return to that average would still require nominal GDP to rise to $35tn or 63% from pre-COVID levels.Even with a staggering 5% annual GDP growth and 2% inflation, it would still take more than seven years to get there. Are stocks really pricing in the year 2028 with 0% discount rate? And if so, what would be the fundamental driver to push stocks even higher from here?  And is there even historic precedent for these kind of growth numbers? In the post WWII period, there have been only two instances where economic expansion was that high for a prolonged period (see Exhibit 8).After WWII ended, the US saw a few years of moderate growth as government spending plummeted, followed by very high growth rates at around 6.9% between 1949 and 1953. This was possible as the US was one of the very few countries where none of the infrastructure had been destroyed and the rest of the world had to be rebuilt. However mathematically, even a repetition of the 1949-53 growth period over the coming years would not be enough to justify current stock prices as it lasted for “only” four years before the US fell into another recession.From 1958-1969, the US economy was able to grow close to 5% with a brief monetary recession in 1960. In our view, this 1960s growth period is the only one that reflects the magnitude and length needed to get US GDP back in line with current equity prices. However, the economic environment of the 1960s looked very different from where we are now. More specifically, the US exited WWII with record debt to GPD of over 100%. However, it then immediately cut spending (which resulted in the slower growth rates in the immediate years after WWII) and reduced debt. Inflation also picked up, which, to some extent, helped reducing debt even further[1]. By 1959, the US government had reduced its debt held by the public to 44%, and it dropped to 27% by the end of the 60s (see exhibit 9).Additionally, 10-year treasury rates average at around 5% during this entire growth period. This is a stark contrast to the 1.5% we are seeing now (which already seem to rattle markets). Furthermore, the FED has no room to the downside, as Fed funds rates are already at zero percent. Hence, the only monetary stimulus that is left is via continued and even more extreme QE. However, as we have shown many times before (see Gold Price Framework Vol. 2: The energy side of the equation, 28 May 2018), QE has always a huge and direct effect on gold prices, and gold is currently not pricing any of that in. Instead, the equity and gold markets seem to be pricing in economic expansion that is driven by anything but more monetary stimulus.Another theme of the great Gatsby scenario is that governments will unleash massive transformation towards a greener future. This will lead to huge infrastructure investments in energy, transportation and commodity space, create jobs and unlock economic growth. While we believe that this is likely to be true, what the market seems to ignore is that this can only be financed with more government debt. Central banks will ultimately have to buy that debt, which has the same effect as QE as it leads to a growing balance sheet. And as we have outlined before, higher QE leads to higher gold prices. So again, if markets are pricing in economic expansion on the back of a “green new deal”, they seem to wrongly assume that this can be done without an effect on gold price.Lastly, there is the idea that the COVID relief checks will continue indefinitely, de facto introducing a sort of Universal Basic Income (UBI). This would have an effect on consumer spending and, thus, corporate revenues. However, currently the US is running the largest deficit in history. If UBI becomes a reality, this would also have to be entirely financed via debt. As mentioned before, markets are not pricing this in, otherwise we would see an effect on gold.Thus, the equity-gold conundrum doesn’t disappear in the great Gatsby scenario. In fact, we think that if we see strong economic growth over the coming years, it will entirely be debt financed and as a consequence gold should outperform stocks, not the other way around.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":107764648,"gmtCreate":1620540922784,"gmtModify":1704344805537,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"Go for it","listText":"Go for it","text":"Go for it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/107764648","repostId":"1106882084","repostType":4,"isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374257611,"gmtCreate":1619450791633,"gmtModify":1704724153845,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>cry tiger","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>cry tiger","text":"$Tiger Brokers(TIGR)$cry tiger","images":[{"img":"https://static.tigerbbs.com/673586a63f14b099924e7a415a100291","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/374257611","isVote":1,"tweetType":1,"viewCount":1052,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573719572697574","authorId":"3573719572697574","name":"张大发同学","avatar":"https://static.tigerbbs.com/3fd7bf41ad5567dd93aae0ed6e28e6fe","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573719572697574","idStr":"3573719572697574"},"content":"I went from 31 to 14","text":"I went from 31 to 14","html":"I went from 31 to 14"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":894990649,"gmtCreate":1628780633881,"gmtModify":1676529854066,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"All the way","listText":"All the way","text":"All the way","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894990649","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://ttm.financial/m/news/2158325931?lang=en_US&edition=fundamental","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1,"symbols_score_info":{"MRNA":0.9,"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2910,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":138407381,"gmtCreate":1621952095743,"gmtModify":1704365073169,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"Go up and down","listText":"Go up and down","text":"Go up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/138407381","repostId":"1150619526","repostType":4,"repost":{"id":"1150619526","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1621951262,"share":"https://ttm.financial/m/news/1150619526?lang=en_US&edition=fundamental","pubTime":"2021-05-25 22:01","market":"us","language":"en","title":"Moderna shares once gained more than 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150619526","media":"Tiger Newspress","summary":"Today Moderna shares once gained more than 4%. Modernasaid Tuesday its Covid-19 vaccine was 100% eff","content":"<p>Today&nbsp;Moderna&nbsp;shares&nbsp;once&nbsp;gained&nbsp;more&nbsp;than&nbsp;4%.&nbsp;</p><p><img src=\"https://static.tigerbbs.com/c4d4545f5ddaf3cc95708b587f6eedb0\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">Modernasaid Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.</p><p>The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partnerBioNTechwere clearedto use their vaccine for 12- to 15-year-olds earlier this month.</p><p>\"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,\" Moderna CEO Stephane Bancel said in a press release. \"We remain committed to doing our part to help end the COVID-19 pandemic.\"</p><p>The two-dose vaccine, which is given four weeks apart, is already authorized for adults.</p><p>U.S. regulators are expected to grant Moderna's request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna shares once gained more than 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna shares once gained more than 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-25 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Today&nbsp;Moderna&nbsp;shares&nbsp;once&nbsp;gained&nbsp;more&nbsp;than&nbsp;4%.&nbsp;</p><p><img src=\"https://static.tigerbbs.com/c4d4545f5ddaf3cc95708b587f6eedb0\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\">Modernasaid Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.</p><p>The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partnerBioNTechwere clearedto use their vaccine for 12- to 15-year-olds earlier this month.</p><p>\"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,\" Moderna CEO Stephane Bancel said in a press release. \"We remain committed to doing our part to help end the COVID-19 pandemic.\"</p><p>The two-dose vaccine, which is given four weeks apart, is already authorized for adults.</p><p>U.S. regulators are expected to grant Moderna's request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150619526","content_text":"Today Moderna shares once gained more than 4%. Modernasaid Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behindPfizer's to demonstrate high efficacy in younger age groups.The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partnerBioNTechwere clearedto use their vaccine for 12- to 15-year-olds earlier this month.\"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,\" Moderna CEO Stephane Bancel said in a press release. \"We remain committed to doing our part to help end the COVID-19 pandemic.\"The two-dose vaccine, which is given four weeks apart, is already authorized for adults.U.S. regulators are expected to grant Moderna's request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578373921153278","authorId":"3578373921153278","name":"djcnsjsjcjd","avatar":"https://static.tigerbbs.com/ef503fc180ab895c78d9ee7a564daafb","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3578373921153278","idStr":"3578373921153278"},"content":"like and comment","text":"like and comment","html":"like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":371497498,"gmtCreate":1618964621214,"gmtModify":1704717520072,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNOW\">$Snowflake(SNOW)$</a>winter snow","listText":"<a href=\"https://laohu8.com/S/SNOW\">$Snowflake(SNOW)$</a>winter snow","text":"$Snowflake(SNOW)$winter snow","images":[{"img":"https://static.tigerbbs.com/67a9078debe32abd7ba2780179c8e0d3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/371497498","isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":357781563,"gmtCreate":1617299401052,"gmtModify":1704698584114,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a>when going up","listText":"<a href=\"https://laohu8.com/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a>when going up","text":"$CN Energy Group Inc.(CNEY)$when going up","images":[{"img":"https://static.tigerbbs.com/3fc6bb6b87b49fccd6b63135ae46cbf4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/357781563","isVote":1,"tweetType":1,"viewCount":1025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":152079134,"gmtCreate":1625246233128,"gmtModify":1703739395984,"author":{"id":"3575416215572570","authorId":"3575416215572570","name":"WilliamTeo","avatar":"https://static.tigerbbs.com/665764fc5f5e89c64f2caa13df0fe1e3","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3575416215572570","idStr":"3575416215572570"},"themes":[],"htmlText":"Go there","listText":"Go there","text":"Go there","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/152079134","repostId":"2148870441","repostType":4,"isVote":1,"tweetType":1,"viewCount":767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}